Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

1.

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF.

Cancer Cell. 2014 Nov 10;26(5):638-52. doi: 10.1016/j.ccell.2014.09.007. Epub 2014 Oct 16.

PMID:
25446897
[PubMed - in process]
2.

Detection of medical errors in kidney transplantation: A pilot study comparing proactive clinician debriefings to a hospital-wide incident reporting system.

McElroy LM, Daud A, Lapin B, Ross O, Woods DM, Skaro AI, Holl JL, Ladner DP.

Surgery. 2014 Nov;156(5):1106-15. doi: 10.1016/j.surg.2014.05.013. Epub 2014 Oct 17.

PMID:
25444312
[PubMed - in process]
3.

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S.

J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16.

PMID:
25440439
[PubMed - in process]
4.

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial.

Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A.

Ann Oncol. 2014 Nov 18. pii: mdu529. [Epub ahead of print]

PMID:
25411413
[PubMed - as supplied by publisher]
5.

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.

J Clin Oncol. 2014 Nov 20;32(33):3697-704. doi: 10.1200/JCO.2014.57.3535. Epub 2014 Oct 6.

PMID:
25287827
[PubMed - in process]
6.

Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy.

Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM.

JAMA Dermatol. 2014 Nov 1;150(11):1209-12. doi: 10.1001/jamadermatol.2014.838.

PMID:
25142409
[PubMed - in process]
7.

A meta-analysis of complications following deceased donor liver transplant.

McElroy LM, Daud A, Davis AE, Lapin B, Baker T, Abecassis MM, Levitsky J, Holl JL, Ladner DP.

Am J Surg. 2014 Oct;208(4):605-18. doi: 10.1016/j.amjsurg.2014.06.006. Epub 2014 Jul 18. Review.

PMID:
25118164
[PubMed - indexed for MEDLINE]
8.

Epiglottic hypoplasia: a natural model for supraglottic laryngoplasty.

Mohamad S, Khan I, Muddaiah A, Shakeel M, Daud A.

J Coll Physicians Surg Pak. 2014 Jul;24(7):528-9. doi: 07.2014/JCPSP.528529.

PMID:
25052981
[PubMed - in process]
9.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA.

Lancet Oncol. 2014 Aug;15(9):954-65. doi: 10.1016/S1470-2045(14)70301-8. Epub 2014 Jul 15. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25037139
[PubMed - indexed for MEDLINE]
10.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A.

Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.

PMID:
25034862
[PubMed - indexed for MEDLINE]
11.

Relationship between the baseline alveolar volume-to-total lung capacity ratio and airway responsiveness.

Kaminsky DA, Daud A, Chapman DG.

Respirology. 2014 Oct;19(7):1046-51. doi: 10.1111/resp.12347. Epub 2014 Jul 3.

PMID:
24995907
[PubMed - in process]
12.

Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins.

Daud AN, Bergman JE, Bakker MK, Wang H, de Walle HE, Plösch T, Wilffert B.

Pharmacogenomics. 2014 May;15(7):1029-41. doi: 10.2217/pgs.14.62.

PMID:
24956255
[PubMed - in process]
13.

Combinatorial approach to treatment of melanoma.

Ashworth MT, Daud AI.

Hematol Oncol Clin North Am. 2014 Jun;28(3):601-12. doi: 10.1016/j.hoc.2014.03.002.

PMID:
24880950
[PubMed - in process]
14.

Melanoma, version 4.2014.

Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M.

J Natl Compr Canc Netw. 2014 May;12(5):621-9.

PMID:
24812131
[PubMed - in process]
15.

Melanoma immunotherapy.

Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S.

Cancer Biol Ther. 2014 Jun 1;15(6):665-74. doi: 10.4161/cbt.28555. Epub 2014 Mar 20.

PMID:
24651672
[PubMed - in process]
16.

Management of a patient with advanced BRAF-mutant melanoma.

Ashworth MT, Daud A.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):315-9; quiz 319.

PMID:
24616537
[PubMed - indexed for MEDLINE]
17.

Radiolytic formation of Fe3O4 nanoparticles: influence of radiation dose on structure and magnetic properties.

Abedini A, Daud AR, Abdul Hamid MA, Kamil Othman N.

PLoS One. 2014 Mar 7;9(3):e90055. doi: 10.1371/journal.pone.0090055. eCollection 2014.

PMID:
24608715
[PubMed - in process]
Free PMC Article
18.

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.

Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF.

J Clin Pharmacol. 2014 Apr;54(4):368-74. doi: 10.1002/jcph.255. Epub 2014 Jan 22.

PMID:
24374975
[PubMed - indexed for MEDLINE]
19.

A review on radiation-induced nucleation and growth of colloidal metallic nanoparticles.

Abedini A, Daud AR, Abdul Hamid MA, Kamil Othman N, Saion E.

Nanoscale Res Lett. 2013 Nov 13;8(1):474. doi: 10.1186/1556-276X-8-474.

PMID:
24225302
[PubMed]
Free PMC Article
20.

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.

Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A.

Cancer Chemother Pharmacol. 2014 Jan;73(1):103-11. doi: 10.1007/s00280-013-2324-5. Epub 2013 Nov 1.

PMID:
24178368
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk